Skip to main content
Hadasit Bio Holding Ltd. logo

Hadasit Bio Holding Ltd. — Investor Relations & Filings

Ticker · HDST-M ISIN · IL0010954050 TA Financial and insurance activities
Open in API
Filings indexed 5 across all filing types
Latest filing 2024-05-05 Regulatory Filings
Country IL Israel
Listing TA HDST-M

About Hadasit Bio Holding Ltd.

https://hadasit.org.il

Hadasit Bio Holding Ltd. is an investment company that operates as a subsidiary of Hadasit Ltd., the technology transfer and innovation arm of the Hadassah University Medical Center. The company focuses on identifying, funding, and developing promising life science technologies originating from the medical center's research and clinical ecosystem. Its primary activity involves making strategic investments in portfolio companies to advance the commercialization of novel diagnostic tools, therapeutic products, and medical devices. By leveraging the scientific and medical expertise of the Hadassah Medical Center, the company aims to bring innovative healthcare solutions to market, with a portfolio that includes ventures in areas such as cell therapy and AI-driven medical technologies.

Recent filings

Filing Released Lang Actions
The company has become a "shell company", the sector classification of the company will be changed as of May 7, 2024
Regulatory Filings
2024-05-05 Hebrew (modern)
HADASIT BIO-M – Discontinuation of Market Making
Regulatory Filings
2023-09-28 Hebrew (modern)
Non-Comliance with the Maintaenance Rules Based on Data as of December 31,2022 but that meet the conditions of the exemption-Notice
Regulatory Filings
2023-01-15 Hebrew (modern)
Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Regulatory Filings Classification · 95% confidence The document is explicitly identified as a "Form 6-K Report of Foreign Private Issuer" filed with the SEC on December 3, 2020. This form is used to report material information that a foreign private issuer is required to disclose to its home country or stock exchange. The content is a press release announcing positive interim results from a Phase II clinical trial for a drug called Allocetra™. This type of announcement, detailing clinical trial results and business updates, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category like ER or IR. However, the core content is a detailed clinical update, which often overlaps with Investor Presentations (IP) or Interim Reports (IR). Since this is a press release announcing specific clinical data and is filed on Form 6-K (a general reporting mechanism), and it is not a comprehensive quarterly report (10-K or IR), the most appropriate classification for a material, non-periodic announcement of clinical progress is often the general Regulatory Filing category (RNS) or, given the focus on financial/operational updates, sometimes an Earnings Release (ER) if it's the primary update for the period. Given the nature of the announcement (clinical trial results, not standard financial performance metrics like revenue/net income), and the filing being a Form 6-K which is a general reporting requirement, RNS is a strong candidate. However, in many financial databases, significant clinical trial updates that drive investor interest are often grouped with Earnings Releases (ER) or Investor Presentations (IP). Since this is a press release announcing results, and it is not a comprehensive Interim Report (IR), and it is not a proxy statement (DEF 14A) or a management discussion (MDA), RNS is the safest fallback. Let's re-evaluate against the definitions. It is not an ER (which is initial announcement of *financial* results). It is not an IR (comprehensive report shorter than a year). It is a material disclosure via Form 6-K, which fits the broad definition of RNS (General regulatory announcements and fallback). I will classify it as RNS as it is a material, non-periodic disclosure filed on a general form (6-K) that doesn't fit the specific financial report codes.
2020-12-03 English
Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
Report Publication Announcement Classification · 98% confidence The document is very short (1754 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K03122020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report for foreign private issuers often filed with the SEC, but here it is being reported to the ISA/TASE). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a general regulatory filing announcement that doesn't fit a more specific category like DIV, ER, or 10-K, RPA is the most appropriate classification based on the 'MENU VS MEAL' rule.
2020-12-03 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.